Cover image for Quarterly Drug Pipeline: July 2026 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-july-2026 Prime...

Editor's message Editorial team Cell therapy= Transplantation of healthy cells to replace or repair damaged ones *Orphan drug status PDUFA= Prescription Drug User Fee Act IV= intravenous...

Prime's recent analysis shows that patients with obesity stopped using a GLP-1 medication within the first few years of treatment.

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended

Prime study finds individuals enrolled in the program for six months who took GLP-1 drugs for obesity lost an average of 22.5 pounds, and 95% of patients remained on GLP-1 therapy

A Prime Therapeutics research poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) explores the cost impact of GLP-1 medications, offering critical...

Emerging evidence shows GLP-1 therapies improve health outcomes, but questions remain about their long-term impact on total health care costs

Injectable glucagon-like peptide-1 agonists, or GLP-1s, were first approved as diabetes medications 20 years ago